AbilityPharma Employee Directory
Biotechnology ResearchCatalonia, Spain11-50 Employees
AbilityPharma is a clinical-stage biotechnology company based in Cerdanyola del Vallès, Catalonia, Spain, focused on developing first-in-class oncology therapies to address unmet medical needs. Its lead asset, ABTL0812, is in an international phase 2b trial for metastatic pancreatic cancer in combination with FOLFIRINOX, with participating centers across Spain, France, the United States, and Israel. ABTL0812 is described as killing tumor cells via cytotoxic autophagy by inhibiting the Akt/mTOR axis and inducing endoplasmic reticulum stress, with additional immunomodulatory effects that may influence responses to chemotherapy and immunotherapies. The company envisions potential applications across several cancer types, including lung, endometrial, pancreatic, and others, where the asset could be used as a first-line or maintenance therapy, alone or in combination. It has pursued regulatory designations such as Orphan Drug Designation from the US FDA and EMA for pancreatic cancer, neuroblastoma, and biliary tract cancer. A notable recent development is a collaboration with AGC Pharma Chemicals announced in July 2024, expanding its development capabilities in pancreatic cancer.
1-888-653-2347 
support@leadiq.com 
